CF Foundation’s Venture Philanthropy Model Featured on Front Page of The Washington Post

The Cystic Fibrosis Foundation's drug development model, mission and leadership are featured on the front page of The Washington Post today.

| 2 min read

The article, “A venture-capital cure for disease?,” highlights the Foundation's pivotal role in developing breakthrough drugs to treat CF, including the newly approved Orkambi and Kalydeco, the first ever drug to target the underlying cause of the disease.

In the story, the Foundation's president and CEO, Robert J. Beall, Ph.D., explains how venture philanthropy has changed the landscape for CF research and “allowed the foundation to 'supercharge' the search for its ultimate goal; a cure for all patients.”

Emily Schaller, who has been taking Kalydeco since its approval, credits the drug as a life-changer saying “I'm alive, and I've never been more alive because of this drug. I'm now starting a retirement fund, which is something I never thought that I would need.”

The piece also describes how the Foundation's venture model has inspired other rare disease foundations, from the Michael J. Fox Foundation to the Multiple Myeloma Research Foundation to the National Multiple Sclerosis Society, to adopt similar strategies to support the development of new treatments.

Read the story here.

Share this article
About the CF Foundation
Recent news
CF Foundation Awards Advance Improvements in CF Newborn Screening
News | 4 min read
Cystic Fibrosis Foundation Awards 2023 Impact Grants
News | 5 min read
Adult with CF Provides Testimony at Congressional Hearing on the Impact of Antimicrobial Resistance 
News | 3 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.